The shift is twofold: less volume per portion, more protein per portion
Consult with a qualified healthcare provider before considering any treatment option.** #ClinicalData #HealthOptimization #EvidenceBasedApproach Retatrutide Phase 3 Results: 24% Weight Loss and Improved Metrics RETATRUTIDE PHASE 3 RESULTS: BY THE NUMBERS Let's break down what the clinical trials actually showed: SURMOUNT-1 Trial Results (68 weeks): Average weight loss: 24% of body weight Participants achieving 25% weight loss: 62% HbA1c reduction: 2.0% average Systolic blood pressure: 9.5 mmHg reduction LDL cholesterol: 19% improvement Comparison to other GLP-1s: Retatrutide: 24% weight loss Semaglutide (Ozempic): 16% weight loss Tirzepatide (Zepbound): 20% weight loss What this means: The triple-pathway approach delivers superior metabolic results
By promoting not only weight loss but also improved overall health, Semaglutide offers a comprehensive solution for individuals seeking to enhance their well-being
Eur Respir J 14:98105 Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Life P, Holmes D, Bonnefoy JY (1995) Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis
It provides skin whitening and brightening benefits to the body through IV or IM infusion
